Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2017 | bb2121: bringing CAR T-cells into the multiple myeloma world

Yi Lin • 24 Jun 2017
EHA 2017
Multiple Myeloma CAR-T Idecabtagene vicleucel

Idecabtagene vicleucel (formerly bb2121) is a chimeric antigen receptor (CAR) T-cell product targeting the B-cell maturation antigen (BCMA), which is universally expressed on plasma cells (myemola cells). At the European Hematology Association (EHA) 2017 meeting, Yi Lin, MD, PhD from the Mayo Clinic, Rochester, MN, presented the latest data from a multicenter study in patients with relapsed/refractory multiple myeloma.

More from Yi Lin

Promising targets in multiple myeloma: BCMA, GPRC5D, and FcRH5 1:41
Promising targets in multiple myeloma: BCMA, GPRC5D, and FcRH5
Yi Lin • 4 Sep 2025
Real-world evidence on the outcomes of CD19 CAR T-cell therapy in aggressive lymphoma 2:02
Real-world evidence on the outcomes of CD19 CAR T-cell therapy in aggressive lymphoma
Yi Lin • 4 Sep 2025
Guidance for junior researchers entering the cellular therapy field 1:55
Guidance for junior researchers entering the cellular therapy field
Yi Lin • 4 Sep 2025
The transformative effect of immunotherapies on the treatment landscape of DLBCL 3:06
The transformative effect of immunotherapies on the treatment landscape of DLBCL
Yi Lin • 4 Sep 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals